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摘  要 
利用靶向性血栓药物实现对实体瘤血管的选择性栓塞是一种新颖的抗肿




























































It is a promising anti-tumor strategy to selectively induce thrombosis in tumor 
vessels by using targeted vascular embolization drug. This strategy used truncated 
Tissue Factor (tTF) as the effector, which combined with tumor vessels targeting 
carrier to selectively induce thrombosis in tumor vasculature and cut off the nutrition 
or oxygen supplies of tumor, subsequently resulted in necrosis of the tumor and 
obtained anti-tumor effects. Current research usually adopted the mode of monomer 
carrier combined with monomer effector whose curative effect would not be satisfied, 
owing to the problem of insufficient binding, low loading drug carrier and slow 
effector targeting enrichment and deficiency concentration. In order to overcome the 
above problem and improve the anti-tumor effects, using water-basic ferrofluids to 
prepare a novel targeting vascular embolization nano-sized drug is introduced for the 
first time in this paper, which have the properties of drug carrier multiple binding; 
high capacity carried and double targeting. 
To verify the possibility of this assumption, MnFe2O4 was prepared by improved 
chemical coprecipitation, used FeCl3·6H2O as iron sources and NaOH as alkali. Acetic 
acid and citric acid was used to modify the property of MnFe2O4 in the process of 
preparation. The diameters of MnFe2O4 were measured under H-600 electron 
microscope. Magnetic property was identified by SQUID. MTT and LDH 
colorimetric assay were used to test its cytotoxicity. Series of experiments in vitro 
were used to test the activity of RGD-tTF-MnFe2O4.The targeted location and tumor 
vascular embolization effect of RGD-tTF-MnFe2O4 was tested in tumor-bearing 
mouse models. The results showed that the synthesized nanoparticle were round or 
ellipse, whose diameter was about 10-25 nm. This water-basic ferrofluids exhibits 
apparent the superparamagnetism and magnetic fluxional phenomenon, which can be 
stably preserved. Procoagulation activity test and activating factorⅩ properties test 
showed that the ability to activate FⅩand induce blood coagulation was preserved 














endothelial cells had no significant effect. Water-basic ferrofluids can also induce 
RGD-tTF to localize cell in vitro in a magnetic field. In the H22 (mouse liver 
cancer)-bearing mouse models, the selective localization was observed both in 
RGD-tTF-MnFe2O4 group and RGD-tTF group in histological studies. Blood vessels 
of the tumors in the treated groups were thrombosed and occluded, which induced 
tumor necrosis, while no thrombosis and cell necrosis was observed in normal tissues. 
Besides, with the effect of magnetic fields the localization of RGD-tTF-MnFe2O4 in 
tumor tissues and thrombosis degree was all better than treated with RGD-tTF alone. 
In summary, RGD-tTF water-basic ferrofluids was successfully prepared by 
nanotechnology, which has both biological and physical targeting. It could selectively 
and effectively induce thrombosis in tumor blood vessels, inhibit the growth of tumor, 
and lead to the necrosis of tumor tissues. These results testified that the combination 
of water-basic ferrofluids and RGD-tTF can implement the double targeting therapy 
of selective thrombosis in tumor blood vessels. 
 


















前言 ····························································································································· 1 
1  磁学基本知识 ·········································································································1 
1.1 磁性的分类 ··································································································· 1 
1.1.1 抗磁性 ······························································································· 2 
1.1.2 顺磁性 ······························································································· 2 
1.1.3 反铁磁性 ··························································································· 2 
1.1.4 铁磁性 ······························································································· 2 
1.1.5 亚铁磁性 ··························································································· 3 
1.2 磁畴及磁滞回线 ··························································································· 3 
2  磁流体的组成 ·········································································································5 
2.1 磁性纳米颗粒 ······························································································· 6 
2.2 基液··············································································································· 6 
2.3 表面活性剂 ··································································································· 6 
3  磁流体的制备方法 ·································································································7 
3.1 机械研磨法 ··································································································· 7 
3.2 真空蒸镀法 ··································································································· 8 
3.3 热分解法 ······································································································· 8 
3.4 化学沉淀法 ··································································································· 8 
3.5 氢还原法 ······································································································· 9 
3.6 电沉积法 ······································································································· 9 
3.7 火花电蚀法 ··································································································· 9 
3.8 等离子体 CVD 法························································································· 9 
3.9 阴离子交换树脂法 ······················································································· 9 
3.10 紫外线分解法 ····························································································10 
4  化学共沉淀法制备水基磁流体 ···········································································10 














   4.2 二次包覆法··································································································10 
4.3 其它包覆法 ··································································································11 
5  磁流体的特点 ·······································································································11 
6  目前存在的问题 ···································································································12 
6.1 超微磁性颗粒的稳定性 ··············································································12 
6.2 表面活性剂的适应特性 ··············································································13 
6.3 载液特性的局限性 ······················································································13 
6.4 聚集作用的影响 ··························································································14 
7  磁流体在肿瘤学治疗领域的应用进展 ·······························································14 
7.1 磁流体热疗 ··································································································15 
7.1.1 磁流体局部热疗 ··············································································15 
7.1.2 磁流体全身热疗 ··············································································16 
7.1.3 磁流体细胞内热疗···········································································16 
7.1.4 肿瘤热疗的自动控温、恒温 ···························································16 
7.2 细胞分离 ······································································································17 
7.3 磁共振成像的造影剂 ···················································································18 
7.4 磁栓塞治疗 ··································································································18 
7.5 药物靶向 ······································································································20 
7.6 磁场对肿瘤的抑制作用 ··············································································20 
8  肿瘤血管靶向治疗 ·······························································································24 
8.1 肿瘤组织血管选择性栓塞的研究进展························································25 
9  本研究的目的和内容 ···························································································27 
第一章 RGD-tTF 水基磁流体的制备及其体外活性鉴定·························29 
一、材料和方法 ·········································································································29 
1  材料 ·····················································································································29 
1.1 菌株、质粒及细胞株 ··················································································29 
1.2 主要试剂及耗材 ··························································································29 
1.3 主要仪器及设备 ··························································································30 
1.4 主要溶液的配制 ··························································································30 
1.5 缩略词表 ······································································································31 














2.1 水基磁流体的制备 ······················································································32 
2.1.1 化学共沉淀生成 MnFe2O4粒子的原理··············································32 
2.1.2 与融合蛋白结合 ··············································································33 
2.2 样品的性能表征 ··························································································33 
2.2.1 样品的形貌和粒径···········································································33 
2.2.2 样品的磁性能 ··················································································33 
2.3 生物兼容性检测 ··························································································34 
2.3.1 MTT 比色分析法 ··············································································34 
2.3.2 乳糖脱氢酶比色法···········································································34 
2.4 tTF 部分的相关活性 ····················································································36 
2.4.1 一步法测定 tTF 的促凝血活性 ·······················································36 
2.4.2 FⅩ活化实验 ·····················································································36 
2.5 RGD 部分的相关活性 ··················································································36 
2.5.1 细胞培养 ··························································································36 
2.5.2 药物的准备 ······················································································37 
2.5.3 融合蛋白的荧光标记·······································································37 
2.5.4 共聚焦扫描显微镜检测···································································38 
2.5.5 流式细胞术 ······················································································38 
2.5.6 磁场对 RGD-tTF-MnFe2O4 在内皮细胞分布的影响······················39 
二、 结果与分析 ·······································································································39 
1  磁流体的表征······································································································39 
1.1 透射电子显微镜（TEM）分析 ··································································39 
1.2 磁性表征 ······································································································41 
1.3 磁响应性和稳定性检测 ··············································································41 
1.4 表面活性剂柠檬酸的影响 ··········································································43 
1.5 无水乙醇的作用 ··························································································44 
2  磁流体生物兼容性检测 ······················································································44 
2.1 MTT 比色分析法··························································································44 
2.2 乳糖脱氢酶比色法 ······················································································44 
3  结合后 tTF 部分的相关活性 ·············································································45 















4  结合后 RGD 部分的相关活性 ············································································46 
4.1 共聚焦显微镜照片 ······················································································46 
4.2 流式细胞仪检测结果 ··················································································47 
4.3 磁场对 RGD-tTF-MnFe2O4 在内皮细胞分布的影响··································48 
三、讨论 ·····················································································································49 
第二章 肿瘤动物模型的建立和病理学分析 ···············································52 
一、材料和方法 ·········································································································52 
1  材料 ·····················································································································52 
1.1 细胞株和实验小鼠 ······················································································52 
1.2 主要试剂及耗材 ··························································································52 
1.3 主要仪器及设备 ··························································································52 
1.4 主要溶液的配制 ··························································································53 
2  方法 ·····················································································································53 
2.1 肿瘤动物模型的建立 ··················································································53 
2.1.1 肿瘤的移植 ······················································································53 
2.1.2 药物的准备 ······················································································54 
2.1.3 玻片的清洗与涂片···········································································54 
2.2 肿瘤动物模型的荧光定位 ···········································································54 
2.2.1 给药 ··································································································54 
2.2.2 肿瘤组织冷冻切片的制备································································55 
2.2.3 切片荧光定位实验···········································································56 
2.2.4 HOECHST 33258 复染 ·····································································56 
2.3 病理学观察 ···································································································56 
2.3.1 HE 染色 ·····························································································56 
二、结果与分析 ·········································································································56 
1  切片荧光定位实验 ······························································································56 
2  融合蛋白在肿瘤组织的定位 ··············································································57 

































 ABSTRACT IN CHINESE  
ABSTRACT IN ENGLISH 
PREFACE················································································································· 1 
Ⅰ BASIC KNOWLEDGE OF MAGNETISM ·························································1 
1.1 CLASSIFICATION OF MAGNETIC PROPERTY ······································· 1 
1.2 MAGNETIC DOMAIN AND MAGNETIC HYSTERESIS LOOP ················ 3 
Ⅱ COMPOSITION OF FERROFLUID ·································································5 
2.1 MAGNETIC NANOPARTICLE ····································································· 6 
2.2 BASE FLUIDS································································································ 6 
2.3 SURFACTANTS ····························································································· 6 
Ⅲ PREPARATION METHODS OF FERROFLUIDS ··········································7 
3.1 MECHANICAL MILLING METHOD ··························································· 7 
3.2 VACUUM EVAPORATION METHOD·························································· 8 
3.3 THERMAL DECOMPOSITION METHOD··················································· 8 
3.4 CHEMICAL PRECIPITATION METHOD ··················································· 8 
3.5 HYDROGEN REDUCTION METHOD ························································· 9 
3.6 ELECTRODEPOSIT METHOD····································································· 9 
3.7 SPARK ELECTRIC EROSION METHOD····················································· 9 
3.8 PLASMA CVD METHOD ············································································ 9 
3.9 ANION EXCHANGE RESIN METHOD ······················································· 9 
3.10 ULTRAVIOLET DECOMPOSITION METHOD ········································10 
Ⅳ WATER-BASIC FERROFLUID PREPARED BY CHEMICAL 
COPRECIPITATION METHOD·············································································10 
4.1 COATING DIRECTLY METHOD ·······························································10 
4.2 SECONDERY COATING METHOD ····························································10 
4.3 OTHER COATING METHOD ······································································11 














Ⅵ THE CURRENT PROBLEMS ············································································12 
6.1 STABILITY OF MAGNETIC ULTRAFINE-PARTICLE ······························12 
6.2 ADAPTATION PROPERTIES OF SURFACTANT ·······································13 
6.3 LIMITATION OF BASIC FLUIDS································································13 
6.4 EFFECT OF AGGREGATION ····································································14 
Ⅶ TRENDS OF FERROFLUIDS APPLICATION ON ONCOLOGY 
TREATMENT ············································································································14 
7.1 MAGNETIC FLUID HYPERTHERMIA·······················································15 
7.2 CELL SEPARATION ·····················································································17 
7.3 CONTRAST AGENT OF MAGNETIC RESONANCE IMAGING ············18 
7.4 EMBOLIZATION TREATMENT WITH MAGNET ·····································18 
7.5 DRUG TARGETING ·····················································································20 
7.6 EFFECT OF MAGNETIC FIELD ON TUMOR············································20 
Ⅷ TUMOR VASCULAR TARGETING THERAPY ············································24 
8.1 TRENDS OF SELECTIVE THROMBOSIS IN TUMOR VESSELS ············25 
Ⅸ THE PURPOSE AND CONTENTS OF THIS THESIS···································27 
CHAPTER I  PREPARATION AND ACTIVITY 
IDENTIFICATION OF RGD-tTF FERROFLUIDS ·······························29 
Ⅰ MATERIALS AND METHODS································································29 
1  MATERIALS ·····································································································29 
1.1 BACTERIUM STRAINS AND VECTORS···················································29 
1.2 REGENTS······································································································29 
1.3 MAIN INSTRUMENT···················································································30 
1.4 PRIMARY SOLUTIONS ·············································································30 
1.5 VOCABULARY BOTH IN ENGLISH AND IN CHINESE ··························31 
2  METHODS ··········································································································32 
2.1 PREPARATION OF FERROFLUIDS····························································32 
2.2 PROPERTY CHARACTERIZATION OF FERROFLUIDS ························33 
2.3 BIOLOGICAL COMPATIBILITY DETECTION ··········································34 
2.4 ACTIVITY OF tTF IN VITRO·······································································36 














Ⅱ RESULTS AND ANALYSIS ·······································································39 
1  PROPERTY CHARACTERIZATION OF FERROFLUIDS ································39 
1.1 TEM ANALYSIS ···························································································39 
1.2 MAGNETIC CHARACTERIZATION ··························································41 
1.3 MAGNETIC RESPONSIVENESS AND STABILITY ································41 
1.4 EFFECT OF SURFACTANT CITRIC ACID ·················································43 
1.5 EFFECT OF ANHYDROUS ALCOHOL ······················································44 
2  BIOLOGICAL COMPATIBILITY DETECTION················································44 
2.1 MTT COLORIMETRIC ASSAY ··································································44 
2.2 LDH COLORIMETRIC ASSAY····································································44 
3  ACTIVITY OF tTF IN VITRO ············································································45 
4  ACTIVITY OF RGD IN VITRO··········································································46 
III  DICUSSION ·································································································49 
CHAPTER II  TREATMENT STUDIES IN MOUSE TUMOR 
MODELS AND PATHOLOGICAL STUDIES ··········································52 
Ⅰ MATERIALS AND METHODS·······························································52 
1  MATERIALS ·······································································································52 
1.1 CELL LINES AND MICE··············································································52 
1.2 REGENTS ····································································································52 
1.3 MAIN INTRUMENTS···················································································52 
1.4 PRIMARY SOLUTIONS ···············································································53 
2  METHODS ··········································································································53 
2.1 TREATMENT STUDIES IN MOUSE TUMOR MODELS ·························53 
2.2 FLUORESCENCE LOCALIZATION IN MOUSE TUMOR MODELS········54 
2.3 EMBOLIZATION OBSERVATION·······························································56 
II  RESULTS AND ANALYSIS ·····································································56 
1  FLUORESCENCE LOCALIZATION OF TISSUE SECTION ··························56 














3  PATHOLOGICAL OBSERVATION·····································································60 

















Degree papers are in the “Xiamen University Electronic Theses and Dissertations Database”. Full
texts are available in the following ways: 
1. If your library is a CALIS member libraries, please log on http://etd.calis.edu.cn/ and submit
requests online, or consult the interlibrary loan department in your library. 
2. For users of non-CALIS member libraries, please mail to etd@xmu.edu.cn for delivery details.
厦
门
大
学
博
硕
士
论
文
摘
要
库
